{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6VxYsJDA","lastupdate":"2024-02-29T00:00:00.000Z","update_date":"2024-02-29T00:00:00.000Z","lastModified":"Jul 1, 2025","active":1,"confidence_score":90,"confidence_score_reason":"markets, not claimed","urlname":"biolojic-design","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$KvsvxrFOVr2smgSVAcLojuMQe5ag3QjuillejgY3wmnkqF3mM87DjN","name":"Biolojic Design","oneliner":"Human Antibody Therapeutics","registrar":"514201391","website":"https://biolojic.com","careerspage":"https://www.biolojic.com/careers","founded_month":11,"founded_year":2010,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"https://www.facebook.com/BiolojicDesign","linkedin":"https://www.linkedin.com/company/18152425","instagram":""},"social":["https://www.linkedin.com/company/18152425","https://www.facebook.com/BiolojicDesign"],"flattenedsociallinks":"https://www.linkedin.com/company/18152425|https://www.facebook.com/BiolojicDesign","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"51-200","employees_exact":94,"patent":1,"raised":3950200,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":null,"about":"Biolojic Design is a biopharmaceutical company dedicated to the development of human antibody-based therapeutics for cancer and other diseases. Biolojic Design has developed a new tool to re-engineer antibodies to bind new epitopes in a process known as re-epitoping. This technology has been shown to yield functional antibodies in difficult targets.\r\n\r\nUsing proprietary algorithms, the company identifies an existing antibody that can be re-epitoped to bind the desired target. The antibody template is then engineered in an iterative computational and experimental approach to bind the desired epitope with high affinity.\r\n\r\nIn 2014, Biolojic partnered with AstraZeneca's MedImmune LLC Biologics unit to discover antibodies for undisclosed targets selected by MedImmune, using Biolojic's computational and biochemical tools.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97235270600","country":null,"address":{"israeli":[{"id":"410d7ebb-76a4-44bc-b472-b573d51d7275","city":"Rehovot","type":null,"address":"HaMada St 12, Rehovot, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"a5b1505a-fec6-43b4-ba13-249548005175","city":"Boston","address":"Boston, MA, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"0MXZMnsVgGPxMkIGPXOBJD1oTg68c0NJHKk39s8Cz4qPhLKKatXTQ2","date":"Jun 3, 2024","link":"https://www.calcalistech.com/ctechnews/article/bybenkovr","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Partnership, AI, Drug Discovery","company":"Biolojic Design","layoffs":"Not mentioned","summary":"Israeli biotech firm Biolojic Design has entered into a collaboration agreement with pharmaceutical giant Merck, potentially worth up to €346 million. The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders. In the first phase, Biolojic Design will receive slightly more than €10 million for the development of two molecules that could serve as the basis for drugs targeting cancer and several immunological disorders. The company will receive additional funding as development progresses, with the full amount contingent on the drug reaching the market and generating sales.","partners":["Merck","Teva"],"customers":"Not mentioned","investors":["aMoon fund","Marius Nacht"],"confidence":9,"key_topics":["AI-Driven Discovery Platform","Therapeutic Antibodies","Cancer Treatment","Immunological Disorders","Collaboration Agreement"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$30 million","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZxslQWIRz7kIoDA1lp1bjueIp8cCa9QH18Kn6NM6HtVZppsZtWbEX8","news_summary":"Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros | CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dw88dxdUD7XdqfiQXipEVXohxEYmTsyUmTU3k6tndU7sOwpa2Vxwn1","date":"Dec 14, 2023","link":"https://en.globes.co.il/en/article-teva-buys-rights-for-israeli-co-biolojics-asthma-treatment-1001465270","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Partnership, Drug Development","company":"Biolojic Design, Teva Pharmaceutical Industries Ltd.","layoffs":"NA","summary":"Teva Pharmaceutical Industries and Biolojic Design have entered into a collaboration agreement for the development of an antibody-based therapy for asthma and atopic dermatitis. As part of the agreement, Teva will make an upfront payment and milestone payments to Biolojic. Biolojic is also eligible to receive tiered royalties in the millions of dollars on product sales if Teva successfully commercializes the therapy. The drug is currently in animal trials.","partners":"Teva Pharmaceutical Industries Ltd.","customers":"NA","investors":"Teva Pharmaceutical Industries Ltd.","confidence":9,"key_topics":"Collaboration, Drug Development, Asthma Treatment, AI in Medicine, Royalties","date_of_event":"December 14, 2023","valuation_amount":"NA","impact_on_company":"growth-positive","investment_amount":"NA","structured_issues":"Partners, Investment","acquisition_amount":"NA","structuredIssuesShow":"#Partners, Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Kd3ytmuqYYbnFWBTDOhFqHCICZcWAh1fcQ27tdqwmSBZFbocHP21Wk","news_summary":"Teva buys rights for Israeli co Biolojic's asthma treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"sVb703ANPj4JEZBRLqRspthgiPaAtVKjzk3Js4eNh7iznYdwcUtJEr","date":"Sep 14, 2022","link":"https://www.prnewswire.com/news-releases/biolojic-design-appoints-ronald-herbst-phd-as-chief-scientific-officer-301623673.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"appointment","company":"Biolojic Design","layoffs":null,"summary":"Biolojic Design has appointed Ronald Herbst, Ph.D. as Chief Scientific Officer. Dr. Herbst brings extensive experience in the biopharmaceutical industry and will play a key role in expanding the companys U.S. operations and advancing computationally designed smart antibodies into the clinic. The appointment demonstrates the companys commitment to delivering smart therapeutics to patients. Dr. Herbsts expertise in cancer and immunology and his track record in drug development will contribute to the companys vision of revolutionizing the treatment of cancer and immunological diseases. Biolojic Design is focused on designing and developing a pipeline of revolutionary therapeutics using AI technology. The company aims to unlock the full potential of well-studied pathways in cancer and autoimmune diseases.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["AI","antibody design","expanding operations","smart antibodies","cancer and immunology"],"date_of_event":"October 3, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"uMEJgIQBziX884QHDbIv3K7dd97trb8qqhN1gJ9LqYWcp3BerftY5n","news_summary":"Biolojic Design Appoints Ronald Herbst, Ph.D., as Chief Scientific Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"IygUWiVwTN7vxQTZ0rGJw9tq6Gzf9vD7cjPp3HB8S5ZzG84I1oppBd","date":"Aug 23, 2022","link":"https://www.genengnews.com/gen-edge/the-logical-song-biolojic-design-reimagines-antibodies-into-smart-therapeutics/","source":"www.genengnews.com","visible":1,"analysis":{"tags":"antibodies, computational design","company":"Biolojic Design","layoffs":null,"summary":"Biolojic Design, a technology company based in Tel Aviv and Boston, is using computational design and AI technology to transform antibodies into intelligent medicinal solutions. The company aims to offer therapies for various diseases, with a focus on cancer and autoimmune illnesses. In April 2022, Biolojic announced that an antibody designed using its AI technology entered a clinical trial, making it the first computationally designed antibody to be tested in humans. The antibody, AU-007, is being developed by Aulos Bioscience, a Biolojic spinoff founded with $40 million in Series A funding from ATP. Biolojic Design is working on a pipeline of antibodies with novel therapeutic properties and is focused on building its own revolutionary antibodies for clinical development.","partners":"Aulos Bioscience","customers":null,"investors":"ATP (Apple Tree Partners)","confidence":9,"key_topics":["Antibodies","Computational design","AI technology","Clinical trials","Therapeutics"],"date_of_event":"April 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$40 million","structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RsERv0qtfHB8t9pm06IXhMVOV7AR2Npylr8YMBluAePjHzzglzZDld","news_summary":"The Logical Song: Biolojic Design Reimagines Antibodies into \"Smart\" Therapeutics","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"li22hdv4JzUVZBYLfv0DnGkxdHm2FCnQb9vJJgovAfJajwGhPqbY3B","date":"Jun 16, 2022","link":"https://www.haaretz.com/israel-news/tech-news/2022-06-16/ty-article-magazine/made-in-israel-first-ai-designed-antibody-could-lead-to-eradication-of-tumors/00000181-6b79-d4a1-a9f9-fbf9ae3e0000","source":"www.haaretz.com","visible":1,"analysis":{"tags":"Drug Development, Clinical Trials","company":"Biolojic Design","layoffs":"Not mentioned","summary":"Biolojic Design, an Israeli biotech company, is conducting clinical trials in Australia for its computer-designed antibody, AU-007, which is aimed at treating terminal cancer. The antibody is designed to activate a molecule known as IL-2, which can eradicate tumors. The trials have shown positive results in mice, leading to the complete elimination of tumors in over half of the subjects. The company has raised about $30 million from investors including aMoon, Keter Plastics, and Prof. Chezy Barenholz. It also co-founded a new company, Aulos Bioscience, with venture capital firm Apple Tree Partners, which invested $40 million to advance AU-007.","partners":"AstraZeneca, Novartis, Nektar Therapeutics, Eli Lilly, Apple Tree Partners","customers":"Not mentioned","investors":"aMoon, Keter Plastics, Prof. Chezy Barenholz, Apple Tree Partners","confidence":9,"key_topics":"Antibody AU-007, Clinical Trials, Computational Biology, Big Data, Cancer Treatment","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$30 million","structured_issues":"Investment, Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9dg0VhbJha97mfbbZL44n5i71jTVnR1BAPeLJv4VOJBVbE8JGgC0v9","news_summary":"Made in Israel: First AI-designed antibody could lead to eradication of tumors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"iE90nKat72vIcc70zc68WjXEj8rEXzveq6Pshqdxq02Su47y8QGkOZ","date":"Apr 5, 2022","link":"https://www.prnewswire.com/news-releases/first-ever-computationally-designed-antibody-created-by-biolojic-design-entering-human-clinical-trial-in-cancer-patients-301517389.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"computational design, antibodies, smart therapeutics","company":"Biolojic Design","layoffs":null,"summary":"Biolojic Design, a technology company, announced that a computationally designed antibody will enter a clinical trial. The antibody, AU-007, was designed to eradicate solid cancer tumors by harnessing the bodys own interleukin-2 (IL-2). The antibody was transferred to Aulos Bioscience, a Biolojic spinoff, for clinical trials. Biolojic Design has partnerships with Nektar Therapeutics and Eli Lilly for the development of antibodies against autoimmune diseases and diabetes, respectively. Aulos Bioscience received $40 million in Series A funding from ATP to advance AU-007. Biolojic Design is also planning to start clinical trials with the first ever multi-specific antibody in 2023. The company aims to expand its presence and leadership in the U.S. with Boston as its base of operations.","partners":["Aulos Bioscience","Nektar Therapeutics","Eli Lilly"],"customers":null,"investors":"ATP (Apple Tree Partners)","confidence":8,"key_topics":["AI platform","computational design of antibodies","clinical trial","AU-007","partnerships"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$40 million","structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cDUxCbyJV0C7rio8VdeeOim0FwQg71sSoGibQjiCsiuB4Hle68CPRe","news_summary":"First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"826cc10f-d636-4aa9-97b4-95f5933e3ce0","date":"Sep 5, 2021","link":"https://en.globes.co.il/en/article-the-man-making-antibodies-smarter-1001384147","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Drug Development, Artificial Intelligence","company":"Biolojic Design","layoffs":"Not mentioned","summary":"Biolojic Design, a company that develops smart antibodies to treat a variety of diseases, is working to revolutionize the pharmaceutical industry. The company uses computational mathematics, big data, and artificial intelligence to develop and program antibodies. Unlike traditional antibodies, these smart antibodies can adapt to changing situations. Biolojic Design has already signed collaboration agreements with pharmaceutical giants like Eli Lilly and Nektar Therapeutics. The company has also raised over $120 million in funding.","partners":["Eli Lilly","Nektar Therapeutics","Apple Tree Partners"],"customers":"Not mentioned","investors":["Eli Lilly","Nektar Therapeutics","Apple Tree Partners","aMoon fund"],"confidence":9,"key_topics":["Drug Development","Artificial Intelligence","Antibodies","Pharmaceutical Industry","Clinical Trials"],"date_of_event":"September 5, 2021","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Over $120 million","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"B4Ue92bmm8FerCxlgAb7NxdksfewOozffityobbAQ7uXobB4FGleIh","news_summary":"The man making antibodies smarter","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"04a5b8e2-c8b0-4404-af12-de2460b24a04","date":"Aug 27, 2021","link":"https://www.globes.co.il/news/article.aspx?_atscid=7_134353_204082920_1946425_0_Txtetaxjxdshwhus8sp&did=1001382802","source":"www.globes.co.il","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"0IG7YVfNL0iAeARuaNEFrhIjs5h89C28VWfpuU6LLUeEvalsSGY3Zl","news_summary":"הסיפור המדהים על המרדף אחר נוגדן שיציל את העולם ממחלות","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"c2d4eb21-86bd-4634-bc45-544cc3db8b0f","date":"Mar 8, 2021","link":"https://www.prnewswire.com/news-releases/lilly-and-biolojic-design-announce-research-collaboration-to-discover-and-develop-antibody-therapies-for-diabetes-301242715.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"research collaboration, license agreement, antibody-based therapy, diabetes","company":"Eli Lilly and Company","layoffs":null,"summary":"Eli Lilly and Biolojic Design have announced a research collaboration and license agreement to develop a potential antibody-based therapy for diabetes. Biolojics AI-based multibody platform will be used in the discovery and development process. Under the agreement, Lilly will pay research fees and Biolojic is eligible to receive up to $121 million in potential development and commercialization milestones. Biolojic may also receive royalties on product sales. The specific targets for the therapy were not disclosed. The collaboration allows Lilly to explore novel methods for developing new medicines, while Biolojic can apply its platform to design potential therapies for diabetes.","partners":"Biolojic Design Ltd.","customers":null,"investors":null,"confidence":9,"key_topics":["Research collaboration","AI-based multibody platform","Antibody-based therapy","Diabetes","Biolojic Design Ltd."],"date_of_event":"March 8, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ooOLejV3skDdTlDX2ZjGjDDvT8w5lPyuu62qYgjpY0Ed7Y7HXkn6t6","news_summary":"Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"qC9av4eX8SXIVN8xjdrTYTxg1YsqGYVr0eMItvQOEnUaGlQYfDxMTI","date":"Feb 25, 2021","link":"https://www.globenewswire.com/news-release/2021/02/25/2182286/0/en/Biolojic-Design-Enters-a-Research-Collaboration-and-License-Option-Agreement-with-Nektar-Therapeutics-to-Develop-Computationally-Designed-Antibodies-Against-a-Novel-Target-for-the-.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"research collaboration, license option agreement","company":"Biolojic Design","layoffs":null,"summary":"Biolojic Design has entered into a research collaboration and license option agreement with Nektar Therapeutics to discover and develop agonistic antibodies for the treatment of autoimmune disease. The financial terms of the transaction were not disclosed. Biolojic Designs AI-based platform designs antibodies that target specific epitopes with precision and carry out functions previously not possible. The collaboration with Nektar allows Biolojic to leverage their computational capabilities and assets to investigate a new target for the potential treatment of autoimmune disease.","partners":"Nektar Therapeutics","customers":null,"investors":null,"confidence":9,"key_topics":["Biotechnology","Antibodies","Autoimmune disease","Research collaboration","AI-based platform"],"date_of_event":"February 25, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4wiB9wHkOIS659bvChYzmaOzP9zrRuAEBqYExYhofPZ2tP3FljemPT","news_summary":"Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a44e2c89-23d0-480c-b24d-c9ba4439e6fd","date":"Jan 7, 2021","link":"https://www.prnewswire.com/il/news-releases/atp-and-biolojic-design-launch-aulos-bioscience-to-develop-highly-differentiated-il-2-antibody-approach-to-fighting-cancer-862640724.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"biotechnology, therapeutics","company":"Aulos Bioscience","layoffs":null,"summary":"Aulos Bioscience, a new company created with $40 million in Series A funding from ATP and Biolojic Design, is developing IL-2-binding monoclonal antibodies as therapeutics against solid tumors. The antibodies are computationally designed to redirect IL-2 to effector T-cells and away from regulatory T-cells, potentially enhancing immune activation. Aulos Bioscience aims to revolutionize cancer treatment and plans to start human trials later this year. The company will be based in Cambridge, MA, and will be presented at the J.P. Morgan Healthcare Conference on January 14, 2021.","partners":["Biolojic Design"],"customers":null,"investors":"ATP","confidence":9,"key_topics":["immuno-oncology","IL-2-binding monoclonal antibodies","computational antibody design","cancer treatment","J.P. Morgan Healthcare Conference"],"date_of_event":"January 8, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$40 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2xREjXi8L1gv3TvKoO6P52RQiLbiGcrux7eAxbbOL5Df3bjBteyBDt","news_summary":"ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":11,"techcommunityinvolvement":null,"mediagallery":[{"id":"b4b1946f-5ed7-4e7e-aa5e-be2671cfb27f","timestamp":"2021-01-10 14:47:54.000000","resources_type":1,"resources_title":"","resources_file_name":"$4sMLtUDIpGF052qN6zG1MffFxVbZbTS1cm44tQoDPf5M3AMcwSjLcP","alt":"","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$4sMLtUDIpGF052qN6zG1MffFxVbZbTS1cm44tQoDPf5M3AMcwSjLcP","url":"https://storage.googleapis.com/clean-finder-353810/$4sMLtUDIpGF052qN6zG1MffFxVbZbTS1cm44tQoDPf5M3AMcwSjLcP"}],"tags":["bioconvergence","therapeutics","bioinformatics","decision-support","nanotechnology","robotics","digital-healthcare","drug-discovery","immunology","healthcare","cancer-therapy","antibodies","artificial-intelligence","pharma-companies"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":[{"date":"2010-11-01","name":"Re-engineer antibodies to bind new epitopes","tags":["algorithms","antibodies","bioinformatics"],"category":"Life Sciences & Biotechnology","tto_logo":"/image_cloud/birad_tto_logo_e0195f9e-6016-11e8-aa84-41fdcbb0dda6","university_logo":"/image_cloud/birad_institution_logo_e0195f9e-6016-11e8-aa84-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":[],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":4,"lastfunding":"$7.5M","totalrounds":3,"fundingstage":"Seed","totalfunding":"$3.95M","publicinvestors":4,"lastpublicfunding":7500000,"totalpublicrounds":3,"totalpublicfunding":3950200},"team":[{"name":"Yanay Ofran, Prof.","email":"yanay@biolojic.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgN6Q6_8IDA","bounced":false,"claimed":0,"founder":1,"urlname":"yanay-ofran-prof","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAnt_sqgoM","position":"Founder & CEO","last_name":"Ofran, Prof.","claimtoken":"wEToNk4LkZdWUDO4hQUH7gnvEYS3mLLwHsHWtfUim5DptJfhKc4P4M","first_name":"Yanay","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yanay-ofran-1ab72955/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-11-15 12:39:42.000000","initials":"YO","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Avi Molcho","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoKmI7Z8KDA","bounced":false,"claimed":0,"founder":1,"urlname":"avi-molcho-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgyZ2K5ggM","position":"Co-founder (No longer with the company)","last_name":"Molcho","claimtoken":"uz7FMvQZ1ndbXRQrqT18ePAiKz8ZyrfCFp4DSugHcw4AlEXuquM3mY","first_name":"Avi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/avi-molcho-552820b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-15 12:40:20.000000","initials":"AM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Micah Pearlman","email":"micah@biolojic.com","phone":"","gender":"Male","userid":"GLAy6bTIyESSp3jgEG03dxOKseWjE4tuDxvPsNdTDuvPm2zcBC43R1","bounced":false,"claimed":1,"founder":0,"urlname":"micah-pearlman","visible":1,"memberid":"M5jmmULMcCkAOYF7wrzk0wXFpXqBf6tChxha8thIM3MHxEnXL1VSRq","position":"COO","last_name":"Pearlman","claimtoken":"yCzSIBmttkpzXA1PkoXrnSDgyqJYh1zBJNj7z5OuGfboKJs9NabSSM","first_name":"Micah","picturekey":null,"claimeddate":"2025-06-18","linkedinurl":"https://www.linkedin.com/in/micah-pearlman/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2025-06-17 07:03:47.000000","initials":"MP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Ronald  Herbst","email":"ronald@biolojic.com","phone":"","gender":"Male","userid":"GNtfJyAMQ5mxDzMgABH08ZJX5aoAQ0ERCnmsRhghKeexKsaYO027u6","bounced":false,"claimed":null,"founder":0,"urlname":"ronald-herbst","visible":1,"memberid":"xyRePZrUq9yBWrzD9lir1Ei619ro6cV6PUpKsrU3F1SaGWwLrphQUB","position":"CSO","last_name":"Herbst","claimtoken":"CmxbDNxSLshNMWGefOsf0NINH3Qy1gmS4a274s4GMS3vpiaGqyoxA5","first_name":"Ronald ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ronald-herbst-28593a7/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2022-11-15 12:51:20.000000","initials":"RH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Noa  Turgeman","email":"noa@biolojic.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4PSuotgIDA","bounced":false,"claimed":0,"founder":0,"urlname":"noa-turgeman","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgnJCVrQgM","position":"HR & Operations Manager","last_name":"Turgeman","claimtoken":"ZOXX2CJSqOYTUxevAmg141MJWuJfmlbBWOLdAuALuFuAiYrmm1PSkT","first_name":"Noa ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/noa-turgeman-67251133/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-15 12:40:42.000000","initials":"NT","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2020-03-26T00:00:00.000Z","crunchbaseid":"biolojic-design","lastupdator":"Matan Eblagon","lastupdator_email":"matane@sncentral.org","creator":null,"creator_email":null,"createdate":"2015-01-08T00:00:00.000Z","biverification":"Jenny Sotnik-Talisman","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"w53CTQ1URZnfu7ukjjDG6R8vN5OOdYAbooUINXpMYaGTZNZyn87d9s","date":"Mar 2025","amount":"$7.5M","source":"https://www.cbinsights.com/company/biolojic-design + https://pitchbook.com/profiles/company/230869-90#timeline","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":7500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"rFUXM6zPka9hxSOsMMzR0gW9In0d5ThnxkX4yvfHSmhDCrzcGFd3gc","date":"Jan 2023","amount":"Undisclosed","source":"https://www.westerntech.com/companies?region-collection=middle-east","eventtype":"FundingRoundEvent","investment":[{"name":"Western Technology Investment","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/western-technology-investment","logokey":"$wZ2h48QyEcuOhlE7ftfIHidd5wdtrdc9KV7XHQyE2KD8IcpJFUTrkj","tagline":null,"urlname":"/investor_page/western-technology-investment","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkLysmsgLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5pqDDIFClZF893Hx2UJasSZp2Cz7zhqhhnWO1YmvlUgXvzjMDSUG3k","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$wZ2h48QyEcuOhlE7ftfIHidd5wdtrdc9KV7XHQyE2KD8IcpJFUTrkj","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC75p21Cww","date":"Jan 2021","amount":"$3.95M","source":"https://www.ourcrowd.com/companies/biolojic-design","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c436c00c-0573-4b5b-9692-2e9f949e51f9","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"","followupcaption":""},{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c85399b4-2745-43d8-b953-92c17dc504bb","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":""},{"name":"Winnovation","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/winnovation","logokey":"$djJO4nZfhVC52OwMw5eSYudPAJTRIXoECRM1ubzWKZO9B2aBhXbu9P","tagline":null,"urlname":"/investor_page/winnovation","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKWv44QJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"eb26f0ca-fbaa-4b5a-8434-3cb312cdcd1a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$djJO4nZfhVC52OwMw5eSYudPAJTRIXoECRM1ubzWKZO9B2aBhXbu9P","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Equity crowdfunding","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3950200,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"11/2010","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Biolojic Design","logourl":"https://storage.googleapis.com/clean-finder-353810/$KvsvxrFOVr2smgSVAcLojuMQe5ag3QjuillejgY3wmnkqF3mM87DjN","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$KvsvxrFOVr2smgSVAcLojuMQe5ag3QjuillejgY3wmnkqF3mM87DjN","seoabout":"Biolojic Design is a biopharmaceutical company dedicated to the development of human antibody-based therapeutics for cancer and other diseases. Biolojic De...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Decision Support","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Machine Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA>Medical Decision Support#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Machine Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA/Medical Decision Support#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Machine Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]},{"title":"Digital Healthcare","key":"0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare","children":[{"title":"Medical Decision Support","key":"0-0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare>Medical Decision Support"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"},{"title":"Biotechnology","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]},{"title":"Artificial Intelligence","key":"0-1","path":"TechnologyClassificationModel>Artificial Intelligence","children":[{"title":"Machine Learning","key":"0-1-0","path":"TechnologyClassificationModel>Artificial Intelligence>Machine Learning"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Decision Support","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Machine Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development","Digital Healthcare","Medical Decision Support"],"coreTechnology":["Biologicals","Molecules","Artificial Intelligence","Machine Learning"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Biotechnology"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"w53CTQ1URZnfu7ukjjDG6R8vN5OOdYAbooUINXpMYaGTZNZyn87d9s","date":"Mar 2025","amount":"$7.5M","source":"https://www.cbinsights.com/company/biolojic-design + https://pitchbook.com/profiles/company/230869-90#timeline","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Debt Financing","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":7500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"rFUXM6zPka9hxSOsMMzR0gW9In0d5ThnxkX4yvfHSmhDCrzcGFd3gc","date":"Jan 2023","amount":"Undisclosed","source":"https://www.westerntech.com/companies?region-collection=middle-east","eventtype":"FundingRoundEvent","investment":[{"name":"Western Technology Investment","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/western-technology-investment","logokey":"$wZ2h48QyEcuOhlE7ftfIHidd5wdtrdc9KV7XHQyE2KD8IcpJFUTrkj","tagline":null,"urlname":"/investor_page/western-technology-investment","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkLysmsgLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5pqDDIFClZF893Hx2UJasSZp2Cz7zhqhhnWO1YmvlUgXvzjMDSUG3k","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$wZ2h48QyEcuOhlE7ftfIHidd5wdtrdc9KV7XHQyE2KD8IcpJFUTrkj","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC75p21Cww","date":"Jan 2021","amount":"$3.95M","source":"https://www.ourcrowd.com/companies/biolojic-design","eventtype":"FundingRoundEvent","investment":[{"name":"OurCrowd","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/ourcrowd","logokey":"$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","tagline":null,"urlname":"/investor_page/ourcrowd","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP7H-oQKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c436c00c-0573-4b5b-9692-2e9f949e51f9","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7IbHrXXd8dSbWrifZtvAYNCvwQvEjxCgGJeOg7DXKENs3TbpV3W9g1","leadcaption":"","followupcaption":""},{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"c85399b4-2745-43d8-b953-92c17dc504bb","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":""},{"name":"Winnovation","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/winnovation","logokey":"$djJO4nZfhVC52OwMw5eSYudPAJTRIXoECRM1ubzWKZO9B2aBhXbu9P","tagline":null,"urlname":"/investor_page/winnovation","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKWv44QJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"eb26f0ca-fbaa-4b5a-8434-3cb312cdcd1a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$djJO4nZfhVC52OwMw5eSYudPAJTRIXoECRM1ubzWKZO9B2aBhXbu9P","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Equity crowdfunding","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":3950200,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}